BPC-157 Human Studies: What the Evidence Shows

BPC-157 human studies exist, but none gives a reliable answer about healing or long-term safety. Three peer-reviewed reports describe 31 people who received BPC-157 in uncontrolled settings; 30 contributed follow-up or outcome data, because one of the 17 knee patients could not be reached. The best-known safety pilot included only two. Two other small enema studies appear in the FDA's inventory, mainly through meeting abstracts. A newer 120-person hamstring trial is recruiting but has no results. The human evidence is a starting point, not proof of benefit or a settled risk profile.

The two-person BPC-157 safety study

The study people cite most often asked a narrow question: what happened during two intravenous infusions in two adults? It did not test an injury, compare BPC-157 with a placebo, or measure whether anyone healed faster.

In the 2025 pilot by Edwin Lee and Kailynd Burgess, a 58-year-old man and a 68-year-old woman received 10 mg by intravenous infusion on day one and 20 mg on day two. The paper described both as healthy and did not report formal exclusion criteria. Both had received intravenous BPC-157 before entering the study, so this was not their first exposure. Follow-up ended the next day.

There was no efficacy endpoint, meaning a planned measure of whether a treatment works. The main outcome was short-term safety, judged through vital signs, symptoms, and biomarkers—blood measurements that can hint at stress on an organ. Here is the whole safety result in plain language:

That is useful as an observation. It shows that these two previously exposed adults did not have an obvious short-term problem during the study. It cannot estimate how often side effects occur, rule out a rare reaction, or say what happens with repeated use. It also says nothing about oral or subcutaneous dosing, which means an injection under the skin. A May 2026 review reached a similar practical limit: it called human drug-processing data critically underdeveloped and found that none of the three published reports used a standardized pharmaceutical preparation.

What BPC-157 human studies actually show

FDA staff found five clinical studies in its literature search. That sounds larger than it is. The studies used different routes, asked different questions, and offered little systematic follow-up.

The three full journal reports are the knee chart review, the bladder pilot, and the intravenous pilot. In the 2021 knee report, 12 people received BPC-157 alone and four received it with thymosin beta-4. There was no placebo group and no standard pain scale. The 2024 bladder report followed 12 women after a single procedure, again without a comparison group. Neither design can separate a drug effect from the procedure, expectation, other care, or the natural course of symptoms.

For a closer look at reported reactions, see BPC-157 side effects. The broader BPC-157 peptide therapy guide explains the animal and cell research behind the interest.

Combination products raise one more evidence problem. Four people in the knee chart review received two peptides, so their results cannot show which one mattered. KLOW contains BPC-157, TB-500, GHK-Cu, and KPV. The human reports above did not test that four-peptide blend, so they cannot show what it adds over one compound alone.

What changed in 2026

As of September 9, 2026, the day this article was written, two BPC-157 studies were visible on ClinicalTrials.gov, but neither supplied a completed result. The older oral Phase 1 record, NCT02637284, still had unknown status, an estimated enrollment of 42, and no posted results. A newer Phase 2 hamstring trial, NCT07437547, was recruiting toward an estimated 120 adults and comparing 14 days of under-the-skin BPC-157 with placebo alongside the same rehabilitation program. Its primary completion was estimated for February 2027. A registry record is a study plan, not evidence that the treatment worked.

For its July 23 advisory meeting, the FDA staff briefing counted the five small human studies above and concluded that the clinical safety information was insufficient to characterize BPC-157's safety profile. The committee's compounding-list recommendation was advisory. It was not FDA approval, and it did not change the quality of the human data.

How the gray market misreads the evidence

The usual leap is simple: two people had no immediate adverse events, so the peptide must be safe and effective. The paper supports only the first half of that sentence, and only for two people over three days. Tolerability is not proof of benefit.

The second leap treats rat tendon experiments as though they were human injury trials. On July 23, 2026, a study of 32 rats with repaired Achilles tendons compared BPC-157, TB-500, both together, and a control. The combination was no better than either peptide alone, and only the TB-500 group showed a statistically significant advantage over control in maximum load before failure. That is an interesting animal result. It cannot predict recovery in a person.

What a provider has to weigh

The honest takeaway is not that BPC-157 has been shown to fail. It is that the studies are too small and too uneven to settle benefit, common side effects, rare harms, or long-term use. A provider has to weigh that uncertainty against the person's health history, current medicines, goals, and established options.

BPC-157 has never had a U.S.-approved product, and the compounded formulation offered here is not FDA-approved. Regulatory status is one input, not a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

One separate rule for tested athletes

The 2026 World Anti-Doping Agency list names BPC-157 under S0 and makes it prohibited at all times, both in and out of competition. A prescription does not erase an anti-doping rule.